Roche ganciclovir oral prodrug will be compared to I.V. ganciclovir in Phase II CMV trial.
Executive Summary
ROCHE PHASE II PRODRUG GANCICLOVIR STUDY IN CMV RETINITIS will compare oral ganciclovir prodrug to the I.V. formulation of ganciclovir (Cytovene) as induction therapy for the treatment of newly diagnosed not immediately sight-threatening cytomegalovirus retinitis in AIDS patients.